Not yet Puntuación de calidad: 42/100

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

International Journal of Molecular Sciences · 2020

KeyPRP Platelet-Rich PlasmaRCT Randomised Controlled Trial

A widely-cited PRP mechanism review, not a clinical trial, it explains the biology, not whether PRP actually works for your patient.

sports-medicinerehabilitationtendinopathyosteoarthritislow-back-painpain-science

El estudio

Narrative review (non-systematic), no original patient cohort, synthesizes in vitro, animal, and human PRP literature on formulation and mechanism.

Qué encontraron

No quantitative clinical outcomes are reported. The review summarizes proposed mechanisms (platelet growth factor release, leukocyte-driven immunomodulation, serotonin/pain effects, angiogenesis) and argues that PRP formulation variables (platelet dose, leukocyte content) explain inconsistent clinical results across studies.

El análisis

This is a mechanistic/narrative review, not a controlled study, there is no described systematic search strategy, no risk-of-bias assessment, and no pooled effect estimates, so it cannot itself establish efficacy. Its value is conceptual: explaining why heterogeneous PRP preparations produce conflicting RCT results, not demonstrating that any specific PRP protocol works. The abstract explicitly flags that non-clinical (in vitro/animal) findings often fail to translate to human outcomes, which is an honest and important caveat but also underscores the evidence gap.

La limitación

It doesn't tell you which PRP formulation (platelet count, leukocyte-rich vs. -poor, activation method) actually improves patient-relevant outcomes for a given condition, that requires standardized-formulation RCTs with clinical endpoints, which this review does not provide.

Estudio de referencia

Sits within the long-running PRP classification debate (e.g., Mishra/DEPA-type classification systems) that arose precisely because unstandardized formulations made trials like those in Achilles and patellar tendinopathy hard to compare or replicate; this paper extends that mechanistic rationale rather than resolving the RCT heterogeneity itself.

Qué hacer el lunes

No, this doesn't change Monday's practice. It's background reading that should make clinicians more skeptical of generic 'PRP' as a single intervention and more attentive to reported formulation details when appraising any individual PRP trial or product.

Leer la fuente primaria ↗

Los cinco estudios que importan — cada semana, gratis.

Leemos toda la literatura de medicina deportiva, rehabilitación y rendimiento y evaluamos los estudios que merecen tu tiempo.

Recibir el número semanal gratis

Análisis relacionados

Léelo en tu idioma: English · Français · Deutsch · Español · Italiano · Nederlands · Dansk · Svenska